Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB.

Wang, Yi; Pan, Xiaoyan; Ji, Hongying; Zuo, Xiaoli; Xiao, Geng-Fu; Li, Jia; Zhang, Lei-Ke; Xia, Bingqing; Gao, Zhaobing.

Afiliação

Wang Y; Stake Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Pan X; University of Chinese Academy of Sciences, Beijing, China.
Ji H; State Key Laboratory of Medical Neurobiology, Institutes of Brain Science, Fudan University, Shanghai, China.
Zuo X; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
Xiao GF; Stake Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Li J; Department of Pharmacology, The Key Laboratory of Neural and Vascular Biology, Ministry of Education, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, Hebei, China.
Zhang LK; Stake Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xia B; University of Chinese Academy of Sciences, Beijing, China.
Gao Z; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.

Cell Discov ; 9(1): 80, 2023 Jul 28.

Article em En | MEDLINE | ID: mdl-37507399

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article